MoonLake Immunotherapeutics News

MoonLake Immunotherapeutics' Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating

TipRanksMay 2 11:45 ET

Strong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market Potential

TipRanksApr 26 14:55 ET

MoonLake Immunotherapeutics: A Promising Outlook With Sonelokimab's Potential in the HS Market

TipRanksApr 23 06:25 ET

Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimab

TipRanksApr 22 12:35 ET

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow JonesApr 11 07:37 ET

Express News | HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Moomoo 24/7Apr 11 07:27 ET

MoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel Optimism

TipRanksApr 11 06:26 ET

MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment

MoonLake Immunotherapeutics (MLTX) and Komodo Health said Wednesday that they signed a three-year partnership to improve treatment of inflammatory skin and joint diseases. The agreement enables the co

MT NewswiresApr 10 14:02 ET

Express News | Moonlake Immunotherapeutics Penned Three-year Technology Partnership With Komodo Health To Advance Research On Inflammatory Skin And Joint Conditions

Moomoo 24/7Apr 10 07:06 ET

MoonLake Immunotherapeutics Inks Three-year Technology Partnership With Komodo Health to Advance Research on Inflammatory Skin and Joint Conditions

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake to tap into Komodo's technology and real-world data to unlock

GlobeNewswireApr 10 07:00 ET

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow JonesApr 9 06:08 ET

MoonLake Immunotherapeutics: A Strong Buy on Innovation and Strategic Market Positioning

TipRanksApr 9 06:05 ET

Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

Moomoo 24/7Apr 9 05:57 ET

Goldman Starts MoonLake at Neutral, Cites Lead Drug Potential

Seeking AlphaApr 2 11:21 ET

MoonLake Immunotherap Price Target Announced at $62.00/Share by Goldman Sachs

MoonLake Immunotherap Price Target Announced at $62.00/Share by Goldman Sachs

Dow JonesApr 2 07:16 ET

MoonLake Immunotherap Initiated at Neutral by Goldman Sachs

MoonLake Immunotherap Initiated at Neutral by Goldman Sachs

Dow JonesApr 2 07:16 ET

Express News | Goldman Sachs Initiates Coverage On MoonLake With Neutral Rating, Announces Price Target of $62

Moomoo 24/7Apr 2 07:05 ET

Express News | Watching MoonLake Immunotherapeutics; Shares Spike Higher, Traders Circulate Comments From Betaville

Moomoo 24/7Mar 28 12:02 ET

Trending Stocks Today: Nova Lifestyle Shoots up 54.05% Post-Market

March 21st - US stocks trending post-market.Gainers: $Nova Lifestyle(NVFY.US)$ shoots up 54.05% to $2.85 with a turnover of $6.43 million. $FedEx(FDX.US)$ jumps 12.62% to $298.3 with a turnover of $35

moomoo NewsMar 21 18:00 ET

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Yahoo FinanceMar 15 11:36 ET